Amy Paller, MD

Department of Dermatology
Feinberg School of Medicine

Poster(s):

• (101) Improvement in atopic dermatitis signs and symptoms with once-daily and proactive twice-weekly roflumilast cream 0.15% or 0.05%: results from the 52-week phase 3 INTEGUMENT-OLE trial in patients aged ≥2 years
  Wednesday, October 29, 2025

• (102) Caregiver-reported outcomes from the phase 3 INTEGUMENT-PED trial of children aged 2–5 years with atopic dermatitis and treated with roflumilast cream 0.05%
  Wednesday, October 29, 2025